Stefan Angermeier

538 total citations
28 papers, 182 citations indexed

About

Stefan Angermeier is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Stefan Angermeier has authored 28 papers receiving a total of 182 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 15 papers in Gastroenterology. Recurrent topics in Stefan Angermeier's work include Gastric Cancer Management and Outcomes (18 papers), Gastrointestinal Tumor Research and Treatment (15 papers) and Colorectal Cancer Treatments and Studies (11 papers). Stefan Angermeier is often cited by papers focused on Gastric Cancer Management and Outcomes (18 papers), Gastrointestinal Tumor Research and Treatment (15 papers) and Colorectal Cancer Treatments and Studies (11 papers). Stefan Angermeier collaborates with scholars based in Germany, Switzerland and Austria. Stefan Angermeier's co-authors include Ralf‐Dieter Hofheinz, Thorsten Oliver Goetze, Eray Goekkurt, Claudia Pauligk, Thomas J. Ettrich, Nils Homann, Sylvie Lorenzen, Peter Thuss‐Patience, Michael Schenk and Albrecht Kretzschmar and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and BMC Cancer.

In The Last Decade

Stefan Angermeier

24 papers receiving 180 citations

Peers

Stefan Angermeier
Comparison fields: 5 of 19
  • Pulmonary and Respiratory Medicine 138
  • Surgery 98
  • Oncology 94
  • Gastroenterology 60
  • Pathology and Forensic Medicine 24
Replace Alessia D’Ignazio with:
Alessia D’Ignazio Italy
Federica Palermo Italy
Natsumi Tomita Japan
Qi-Yue Chen China
Daniel José Szor Brazil
Jian-Xian Lin China
Evgeny Gotovkin Russia
Dewi Vernerey France
Tomomi Kashiwada Japan
Philipp Schüler Germany
Alessia D’Ignazio Italy View profile →
Citations per field, relative to Stefan Angermeier
Stefan Angermeier · 1×
Citations per year, relative to Stefan Angermeier
Stefan Angermeier · 1×

Countries citing papers authored by Stefan Angermeier

Since Specialization
Citations

This map shows the geographic impact of Stefan Angermeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Angermeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Angermeier more than expected).

Fields of papers citing papers by Stefan Angermeier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Angermeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Angermeier. The network helps show where Stefan Angermeier may publish in the future.

Co-authorship network of co-authors of Stefan Angermeier

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Angermeier. A scholar is included among the top collaborators of Stefan Angermeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Angermeier. Stefan Angermeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study
2024 ·Journal of Geriatric Oncology ·Moying Li, Nadja M. Meindl‐Beinker, (unknown), Johannes Betge, Nadine Schulte, Tianzuo Zhan, Ralf‐Dieter Hofheinz, Arndt Vogel, Stefan Angermeier, Claus Bolling, Maike de Wit, Ralf Jakobs, Meinolf Karthaus, (unknown), Peter Thuss‐Patience, (unknown), H. Bauer, Matthias Ebert, (unknown)
0
2
A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633/DANTE trial, a trial of AIO in collaboration with SAKK.
2024 ·Journal of Clinical Oncology ·Salah‐Eddin Al‐Batran, Sylvie Lorenzen, (unknown), Stefan Angermeier, Thomas J. Ettrich, Nils Homann, Georg Martin Haag, Annika Kurreck, Alexander Stein, (unknown), Ulrich Ronellenfitsch, Thomas Zander, Stefan Kubicka, (unknown), Christina Kopp, Claudia Pauligk, Thorsten Oliver Goetze
1
3
LBA59 Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial
2024 ·Annals of Oncology ·Sylvie Lorenzen, Thorsten Oliver Goetze, Peter Thuss‐Patience, Jorge Riera Knorrenschild, (unknown), (unknown), Thomas J. Ettrich, Ralf‐Dieter Hofheinz, Kim Barbara Luley, Daniel Pink, Udo Lindig, (unknown), Gunter Schuch, Michael Bitzer, (unknown), Stefan Angermeier, Claus Bolling, (unknown), Claudia Pauligk, S-E. Al-Batran
2
4
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)
2024 ·Journal of Cancer Research and Clinical Oncology ·Dominik Paul Modest, Volker Heinemann, (unknown), Stefan Angermeier, (unknown), Oliver Waidmann, Ullrich Graeven, Kai Wille, Volker Kunzmann, Larissa Henze, Carolina Constantin, (unknown), (unknown), (unknown), (unknown), Ivan Jelas, (unknown), Arndt Stahler, Sebastian Stintzing, (unknown)
3
5
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
2023 ·Journal of Clinical Oncology ·(unknown), Tobias Gaska, Maximilian Reichert, Michael Quante, Helmut Oettle, Dirk Waldschmidt, Anke Schlenska‐Lange, Stefan Angermeier, Ludwig Fischer von Weikersthal, W Bohle, Ursula Vehling‐Kaiser, Arndt Stahler, Stephan Kanzler, Christof Lamberti, Uwe Pelzer, Marianne Sinn, Wolfgang Blau, Stefan Boeck, Swantje Held, Volker Heinemann
5
6
Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: The randomized phase 2 IKF-S628 Moonlight trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
2023 ·Journal of Clinical Oncology ·Sylvie Lorenzen, Thorsten Oliver Goetze, Peter Thuss‐Patience, Jorge Riera‐Knorrenschild, Eray Goekkurt, Tobias Dechow, Thomas J. Ettrich, Ralf‐Dieter Hofheinz, Kim Barbara Luley, Daniel Pink, Udo Lindig, Gunnar Folprecht, Gunter Schuch, Michael Bitzer, Volker Heinemann, Stefan Angermeier, Claus Bolling, (unknown), Claudia Pauligk, Salah-Eddin Al-Batran
0
7
1203O FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO
2022 ·Annals of Oncology ·Sylvie Lorenzen, Peter Thuss‐Patience, (unknown), Jorge Riera Knorrenschild, Volker Heinemann, Eray Goekkurt, (unknown), Thomas J. Ettrich, Kim Barbara Luley, (unknown), Udo Lindig, Stefan Angermeier, Oliver Waidmann, Daniel Pink, Claus Bolling, (unknown), Claudia Pauligk, Timo Gaiser, (unknown), S-E. Al-Batran
2
8
Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.
2022 ·Journal of Clinical Oncology ·Salah-Eddin Al-Batran, Sylvie Lorenzen, Peter Thuss‐Patience, Nils Homann, Michael Schenk, Udo Lindig, (unknown), Albrecht Kretzschmar, Eray Goekkurt, Georg Martin Haag, Jorge Riera Knorrenschild, Claus Bolling, Ralf‐Dieter Hofheinz, Stefan Angermeier, Thomas J. Ettrich, (unknown), Christina Kopp, Claudia Pauligk, Thorsten Oliver Goetze, (unknown)
70
9
Nivolumab plus ipilimumab in second-line combination therapy for older patients with esophageal squamous cell cancer (AIO-STO-0117 trial).
2022 ·Journal of Clinical Oncology ·Matthias Ebert, Nadja M. Meindl‐Beinker, Tobias Gutting, (unknown), Johannes Betge, Nadine Schulte, Tianzuo Zhan, (unknown), Ralf‐Dieter Hofheinz, Arndt Vogel, Stefan Angermeier, Maike de Wit, Ralf Jakobs, Meinolf Karthaus, (unknown), Peter Thuss‐Patience, (unknown), (unknown)
1
10
Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: Report of a secondary endpoint of the phase-III FIRE-4 study (AIO KRK-0114).
2022 ·Journal of Clinical Oncology ·Sebastian Stintzing, (unknown), Martin Fuchs, Florian Kaiser, Kathrin Heinrich, Dominik Paul Modest, Ralf‐Dieter Hofheinz, Thomas Decker, Armin Gerger, Stefan Angermeier, Holger Rumpold, (unknown), Leopold Öhler, Birgit Gruenberger, (unknown), (unknown), Thomas Winder, Stefan Kasper, Gerald W. Prager, Volker Heinemann
5
11
Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
2022 ·Journal of Clinical Oncology ·Thorsten Oliver Goetze, Ralf‐Dieter Hofheinz, Harald Schmalenberg, Dirk Strumberg, Eray Goekkurt, Stefan Angermeier, Thomas Zander, Jochem Potenberg, Hans‐Georg Kopp, Daniel Pink, Gabriele Margareta Siegler, Michael Schenk, Ferdinando De Vita, Evaristo Maiello, Timo Gaiser, Disorn Sookthai, (unknown), Claudia Pauligk, Nils Homann, Salah-Eddin Al-Batran
3
12
1443P Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO
2020 ·Annals of Oncology ·Claudia Pauligk, (unknown), Peter Thuss‐Patience, Jorge Riera‐Knorrenschild, Eray Goekkurt, Thomas J. Ettrich, Daniel Pink, Udo Lindig, Kim Barbara Luley, Tobias Dechow, Michael Bitzer, Stefan Angermeier, Nils Homann, Frank Kullmann, Gunter Schuch, Claus Bolling, (unknown), Ralf‐Dieter Hofheinz, Sylvie Lorenzen, S-E. Al-Batran
6
13
1424MO Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma– Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM
2020 ·Annals of Oncology ·S-E. Al-Batran, Ralf‐Dieter Hofheinz, Harald Schmalenberg, Dirk Strumberg, Eray Goekkurt, Stefan Angermeier, Thomas Zander, Jochem Potenberg, H-G. Kopp, Daniel Pink, Gabriele Margareta Siegler, Michael Schenk, F. De Vita, Evaristo Maiello, Timo Gaiser, Disorn Sookthai, (unknown), Claudia Pauligk, (unknown), Nils Homann
5
14
1494P Updated safety data of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma - A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK
2020 ·Annals of Oncology ·S-E. Al-Batran, Sylvie Lorenzen, Peter Thuss‐Patience, Michael Schenk, Eray Goekkurt, Ralf‐Dieter Hofheinz, A. Kretzschmar, (unknown), Claus Bolling, Georg Martin Haag, Stefan Angermeier, Ludwig Fischer von Weikersthal, Wolf O. Bechstein, Andreas Wicki, Alexander Siebenhüner, (unknown), Natsumi Irahara, Claudia Pauligk, (unknown), Nils Homann
5
15
Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKK.
2020 ·Journal of Clinical Oncology ·Salah‐Eddin Al‐Batran, Sylvie Lorenzen, Michael Schenk, Peter Thuss‐Patience, Eray Goekkurt, Ralf‐Dieter Hofheinz, Albrecht Kretzschmar, Claus Bolling, Stefan Angermeier, Andreas Wicki, (unknown), Ekkehard Eigendorff, (unknown), Thomas J. Ettrich, Harald Schmalenberg, (unknown), (unknown), Claudia Pauligk, Thorsten Oliver Goetze, Nils Homann
4
16
Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.
2020 ·Journal of Clinical Oncology ·Nils Homann, Sylvie Lorenzen, Michael Schenk, Peter Thuss‐Patience, Eray Goekkurt, Ralf‐Dieter Hofheinz, Albrecht Kretzschmar, Claus Bolling, Stefan Angermeier, Andreas Wicki, (unknown), Udo Lindig, Daniel Pink, Thomas J. Ettrich, Harald Schmalenberg, (unknown), (unknown), Claudia Pauligk, Thorsten Oliver Goetze, Salah‐Eddin Al‐Batran
10
17
Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.
2019 ·Journal of Clinical Oncology ·Salah‐Eddin Al‐Batran, Claudia Pauligk, Thorsten Oliver Goetze, Jorge Riera‐Knorrenschild, Eray Goekkurt, Stefan Angermeier, Frank Kullmann, Peter Thuss‐Patience, Nils Homann, Thomas J. Ettrich, (unknown), Ralf‐Dieter Hofheinz, Sylvie Lorenzen
4
18
Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study
2019 ·BMC Cancer ·Lukas Perkhofer, Andreas W. Berger, (unknown), Eike Gallmeier, Stefan Angermeier, Ludwig Fischer von Weikersthal, Thorsten Oliver Goetze, Rainer Muche, Thomas Seufferlein, Thomas J. Ettrich
13
19
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK
2019 ·Annals of Oncology ·S-E. Al-Batran, Claudia Pauligk, Ralf‐Dieter Hofheinz, Sylvie Lorenzen, Andreas Wicki, (unknown), Michael Schenk, Peter Thuss‐Patience, Albrecht Kretzschmar, Claus Bolling, Ekkehard Eigendorff, Stefan Angermeier, Daniel Pink, Michael Geißler, Eray Goekkurt, Harald Schmalenberg, (unknown), (unknown), Thorsten Oliver Goetze, Nils Homann
4
20
Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase II trial of the German Gastric Group of the AIO
2019 ·Annals of Oncology ·Sylvie Lorenzen, Claudia Pauligk, Thorsten Oliver Goetze, Jorge Riera Knorrenschild, Eray Goekkurt, Frank Kullmann, Daniel Pink, Thomas J. Ettrich, Nils Homann, Stefan Angermeier, Peter Thuss‐Patience, Udo Lindig, Michael Bitzer, Tobias Dechow, Gunter Schuch, Harald Schmalenberg, (unknown), Ralf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran
1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessia D’Ignazio Breakdown of academic impact, for papers by Federica Palermo Breakdown of academic impact, for papers by Natsumi Tomita Breakdown of academic impact, for papers by Qi-Yue Chen Breakdown of academic impact, for papers by Daniel José Szor Breakdown of academic impact, for papers by Jian-Xian Lin Breakdown of academic impact, for papers by Evgeny Gotovkin Breakdown of academic impact, for papers by Dewi Vernerey Breakdown of academic impact, for papers by Tomomi Kashiwada Breakdown of academic impact, for papers by Philipp Schüler
Rankless by CCL
2026